TL;DR
UCLA has developed DDL-920, a drug that replicates the brain repair effects of physical stroke rehabilitation in mice. This breakthrough could lead to new treatments for stroke patients, pending further safety studies.
UCLA researchers have announced the discovery of DDL-920, the first drug shown to fully mimic the effects of physical stroke rehabilitation in laboratory mice, marking a significant advance in stroke recovery research.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The study, published in Nature Communications, reports that DDL-920 excites parvalbumin neurons in the brain, promoting gamma oscillations that restore lost neural connections caused by stroke. This recovery was observed in mouse models, where movement control improved significantly after treatment.
Lead author Dr. S. Thomas Carmichael, UCLA Neurology professor and chair, explained that the drug targets brain circuits involved in movement and gait, which are typically disrupted after stroke. The drug was developed based on insights into how physical rehabilitation restores brain network coordination.
Why It Matters
This discovery could revolutionize stroke treatment by providing a pharmaceutical option that replicates the benefits of physical rehabilitation, which is often limited in effectiveness and accessibility. If proven safe and effective in humans, DDL-920 could reduce long-term disability for millions of stroke survivors worldwide.
Products Worth Considering
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
Garmin Fenix 8 47 mm AMOLED Sapphire Multisport GPS Smartwatch with Titanium Case and Silicone Band
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
Background
Stroke remains the leading cause of adult disability globally. Currently, recovery relies heavily on physical therapy, which offers modest improvements. Prior research identified that stroke disconnects brain networks, particularly affecting gamma oscillations generated by parvalbumin neurons. The UCLA team’s work builds on this understanding, aiming to create drugs that induce similar neural effects without intensive therapy.
“Our goal is to develop a medicine that can produce the effects of rehabilitation, helping stroke patients regain movement even when physical therapy is limited.”
— Dr. S. Thomas Carmichael
“DDL-920 specifically excites parvalbumin neurons, restoring gamma oscillations and repairing neural connections damaged by stroke.”
— Varghese John, UCLA coauthor
What Remains Unclear
It is not yet clear whether DDL-920 will be safe or effective in humans. Further preclinical studies are needed to assess safety, dosing, and potential side effects before human trials can begin.
What’s Next
Next steps include conducting additional animal studies to evaluate safety and optimal dosing. If these are successful, the researchers plan to initiate early-phase clinical trials in humans within the next two years.
Key Questions
When might this drug be available for human use?
It is still in the early research phase. Human trials are expected to start within the next two years, but widespread availability will depend on trial outcomes and regulatory approval.
How does DDL-920 work to improve stroke recovery?
The drug excites parvalbumin neurons in the brain, restoring gamma oscillations that help reconnect neural networks damaged by stroke, leading to improved movement control.
Can this drug replace physical rehabilitation?
It is too early to say. The drug aims to mimic rehabilitation effects, but further research is needed to determine if it can fully replace or should complement physical therapy.
Are there any risks associated with the drug?
Risks are currently unknown. Safety and side effects must be evaluated through preclinical and clinical trials before any conclusions can be made.
